Tagged with Merck,

Taiwan All country managers of multinational pharma companies need to strike the balance between having a global outlook and adapting to local culture. For BoonHuey Ee, general manager of Merck Biopharma Taiwan, “at first glance, each country might appear to be vastly different with its own incomparable features. However, rather than…

Sweden Anders Wesslau, the newly appointed general manager for Merck KGaA’s business units in Sweden, underlines how Merck’s healthcare business is a well-integrated player in the innovative Swedish life sciences ecosystem, illustrates the company’s innovation partnerships with key research institutions, and how Merck is developing new technologies and solutions with key…

Taiwan BoonHuey Ee, general manager of Merck Biopharma Taiwan, shares her story of joining the affiliate at the beginning of last year and goes on to offer insights on the strengths of Taiwan’s unique positioning. Ee also highlights the excellent performance of Merck Taiwan, its dedication to the island’s own biopharma…

Germany German giant Merck KGaA has announced a EUR one billion investment into its headquarters in Darmstadt, Germany up until 2025.   The aim of Merck’s proposed investment is to secure the future viability of its headquarters as a central science and technology hub and to further expand it, according to…

Diversity Annually, PharmaBoardroom conducts hundreds of interviews with global CEO’s, country managers and industry leaders in the pharma industry. While we have crossed paths with many inspiring females in these positions, out of the top 50 pharma companies, only 3 are headed by women. That is a mere 6% — this…

China This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. We start in China, where the heads of Merck, Ipsen, Chiesi, Gedeon Richter and AbbVie’s Chinese affiliates give their…

France Thierry Hulot, president biopharma of Merck France, explains how France has become more open to diversity, while still needing significant reforms in the healthcare sector to remain competitive. He also shares insights into his career and the learnings from the Levothyrox case.   Overall, we are a very important branch…

Spain Marieta Jiménez, president and general manager of Merck Spain, highlights her three top priorities: innovation, science and technology, and women’s equality. Furthermore, she gives an overview of the need for better collaboration for long-term sustainably of the Spanish healthcare system and breaks down the role of the ClosingGap cluster to…

Algeria Moncef Meklati, Merck’s general manager for North West Africa, discusses the company’s ambitions in the region, the key to successful joint ventures and evolving attitudes to chronic diseases in Algeria.   From the first day I started working for Merck, I’ve been impressed by the strong commitment of my team…

China Rogier Janssens, GM of the Biopharma business of Merck KGaA, Darmstadt, Germany in China, shares the highlights of his first 16 months at the affiliate; the impact of the regulatory changes on the Biopharma business of Merck KGaA, Darmstadt, Germany in China; the significance of the affiliate’s commercial growth as…

Korea Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for companies like Merck to utilize local partnerships.   We are in the process of preparing launches of our new molecules…

Hong Kong Merck Hong Kong’s Hee-sun Lee gives her first impressions of the Hong Kong market, her main priorities, upcoming product launches and tapping into the territory’s R&D ecosystem. Hee-sun, having joined Merck Pharmaceutical Hong Kong in February 2018 from the South Korean affiliate, what are your first impressions of the market…